IGM Biosciences (IGMS) Q3 2024 earnings summary

Executive summary

• Strategic pivot to focus exclusively on autoimmunity, with lead candidates imvotamab and IGM-2644 in Phase 1 trials for SLE, RA, myositis, and planned study in myasthenia gravis by year-end 2024.

• In September 2024, the company reduced workforce and oncology R&D spending, refocused the Sanofi collaboration on immunology, and made leadership changes.

• Initial data from ongoing clinical trials expected by mid-2025.

• Cash runway projected to fund operations into 2027.

• As of September 30, 2024, cash, cash equivalents, and marketable securities totaled $218.8 million.

Financial highlights

• Collaboration revenue was $2.3 million for the nine months ended September 30, 2024, up from $1.5 million year-over-year, with Q3 2024 revenue at $0.5 million.

• R&D expenses for Q3 2024 were $46.1 million, down from $54.8 million in Q3 2023, including $5.5 million in one-time pivot expenses.

• G&A expenses for Q3 2024 were $18.8 million, up from $12.5 million in Q3 2023, including $8.5 million in one-time pivot expenses.

• Net loss for Q3 2024 was $61.4 million ($1.01 per share), compared to $62.0 million ($1.04 per share) in Q3 2023.

• Cash and investments declined from $337.7 million at year-end 2023 to $218.8 million as of September 30, 2024.

Outlook and guidance

• Full year 2024 GAAP operating expenses expected to be $215–$225 million, including ~$40 million in non-cash stock-based compensation.

• Year-end 2024 cash and investments expected to be ~$180 million, sufficient to fund operations into 2027.

• The 2024 restructuring is expected to be substantially complete by June 30, 2025.